General Biotechnology

Patients don’t ask “What’s the patent status?”—they ask, “Will I be able to get my medicine tomorrow?”
That’s the real subtext behind the growing wave of online questions about drug switching. And it’s why the conversation around patents, exclusivity, …

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…

Your drug’s “patent life” isn’t one number in the GCC. It’s a moving target.
If you’re launching (or defending) a branded medicine in the Gulf Cooperation Council, the biggest misconception is simple: patent term is the same everywhere.
In reality, t…

Biopharma teams don’t lose deals because they lack ambition. They lose because timing is misaligned.
In licensing, partnering, and BD strategy, the “pitch” is rarely just a pitch. It’s a calendar—built on patent life, regulatory milestones, and the ung…

OpenAI’s “GPT for life sciences” is getting the headlines—but the real question for drug developers isn’t what it can do in a demo. It’s what it changes in the messy, expensive, failure-prone reality of drug development.
That’s the subtext behind the l…

Biosimilar timelines aren’t linear—so why are outreach strategies?
If you’re trying to reach biosimilar manufacturers, you’re probably doing it the hard way: waiting until a patent expiry date is “close enough,” then assuming the commercial and technic…

AI is quietly becoming the new “KOL” in pharma—and most companies aren’t tracking it.
For years, drugmakers have mapped influence the old way: key opinion leaders, conference circuits, advisory boards, and the slow grind of peer-reviewed credibility. B…

Most pharma teams wait until the patent is already dying. That’s why they miss the money.
In drug development, timing is everything—but in licensing, timing is everything squared. The closer a product gets to patent expiry, the more value concentrates …

Drug patent expiry isn’t a single date—it’s a moving target across jurisdictions, regulatory regimes, and legal timelines. And if your portfolio planning still treats it like a one-size-fits-all calendar event, you’re likely making decisions on incompl…

Generic entry is inevitable—unless you build a moat that can’t be copied.
Most investors and operators obsess over the obvious: composition-of-matter patents, branded label exclusivity, and blockbuster timelines. But in the real world, generics don’t…